Alzheimer's disease
Conditions
Interventions
Case series:No
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Non-disease controls: (1) The age is between 60 and 80 years old; there is no restriction on gender; (2) The researcher's cognition is normal through the test, and the Aß imaging is negative; (3) The written informed consent must be signed by the subject or his legal guardian or caregiver; (4) Blood routine: white blood cell count (WBC) 4~10x10^9/L; platelet (PLT) 100~300x10^9/L; hemoglobin (HB) 120~160 g/L; renal function: serum creatinine is less than or equal to The upper limit of the normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) is less than or equal to the upper limit of the normal range; ECG: no significant abnormality; (5) Willing and able to cooperate with all projects of this research. 2.AD patients/DM patients: (1) Aged 60 to 80 years; there is no restriction on gender; (2) The diagnosis of AD is based on the 2011 National Aging and Alzheimer's Disease Association (NIA-AA) probable AD dementia diagnostic criteria. Diabetes diagnostic criteria are based on the 1999 World Health Organization (WHO) Diabetes Diagnostic Criteria; (3) Brain MRI supports the diagnosis of AD, and there is no evidence of other neurological diseases; (4) The investigator has confirmed that there is no neurological disease, major chronic disease, malignant tumor or acute infectious disease, etc; (5) A written informed consent form must be signed by the subject or his legal guardian or caregiver; (6) Blood routine: white blood cell count (WBC) 4~10x10^9/L; platelet (PLT) 100~300x10^9/L; hemoglobin (HB) 120~160 g/L; renal function: serum creatinine is less than or equal to Upper limit of normal range; Function: Bilirubin, AST(SGOT)/ALT(SGPT) is less than or equal to the upper limit of normal range; ECG: no significant abnormality; (7) Willing and able to cooperate with all projects of this research.
Exclusion criteria
Exclusion criteria: 1. Suffer from serious other neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor endocrine, respiratory system, immunodeficiency and other serious diseases; 2. There are contraindications for PET/CT scanning in candidate subjects. Those who cannot accept repeated intravenous injections; those who may be allergic to the drugs and their components (including those with a history of severe allergies or allergic reactions, especially those who are allergic to the tested drugs); occlusion phobia; 3. In the past year, in addition to participating in the expected radiation exposure of this clinical study, participated in other research programs or clinical care, making the radiation exposure more than the effective dose of 50 mSv; 4. Drug abuse or alcohol abuse for at least 1 month; 5. The venous condition is poor and cannot tolerate repeated venipuncture; 6. The candidate subject has received major surgery within the past 3 months; has received experimental drug or device treatment (with unclear efficacy or safety) within 1 month; 7. The candidate subject has any clinical conditions that the research leader believes that the preparation may cause or have potential harm.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standard uptake value of cerebral cortex and striatum; | — |
Countries
China
Contacts
Public ContactJiang donglang
Huashan Hospital, Fudan University
Outcome results
None listed